Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy Prediction of Selinexor-Based Regimens in Relapsed/Refractory Multiple Myeloma Based on Differential Multigene Expression: A Multicenter Prospective Clinical Study

NCT07514052 is registered in ClinicalTrials.gov with Shanxi Bethune Hospital as lead sponsor.

NCT NCT07514052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07514052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy Prediction of Selinexor-Based Regimens in Relapsed/Refractory Multiple Myeloma Based on Differential Multigene Expression: A Multicenter Prospective Clinical Study
Lead sponsor
Shanxi Bethune Hospital
Phase
Observational
Overall status
Recruiting
Start date
January 1, 2026
Completion date
April 30, 2027
Enrollment
127 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma of bone